Esperion Therapeutics, Inc. Quarterly Operating Income (Loss) in USD from Q1 2012 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Esperion Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q1 2012 to Q3 2024.
  • Esperion Therapeutics, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$16M, a 41.8% increase year-over-year.
  • Esperion Therapeutics, Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was $16.5M.
  • Esperion Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$156M, a 13.3% increase from 2022.
  • Esperion Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$180M, a 20.8% increase from 2021.
  • Esperion Therapeutics, Inc. annual Operating Income (Loss) for 2021 was -$227M, a 86.8% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $16.5M -$16M +$11.5M +41.8% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-07
Q2 2024 $4.95M $2.58M +$39.6M Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-12
Q1 2024 -$34.7M $72.3M +$121M Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-07
Q4 2023 -$156M -$42.4M +$146K +0.34% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-27
Q3 2023 -$156M -$27.5M +$14.1M +33.9% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-07
Q2 2023 -$170M -$37.1M +$15.3M +29.2% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-12
Q1 2023 -$185M -$48.6M -$5.62M -13.1% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-07
Q4 2022 -$180M -$42.5M +$13.1M +23.6% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-27
Q3 2022 -$193M -$41.6M +$14.1M +25.3% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-07
Q2 2022 -$207M -$52.4M -$19.8M -61% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-01
Q1 2022 -$187M -$43M +$39.8M +48.1% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-09
Q4 2021 -$227M -$55.6M +$39.9M +41.8% Oct 1, 2021 Dec 31, 2021 10-K 2023-02-21
Q3 2021 -$267M -$55.7M +$24.8M +30.8% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-01
Q2 2021 -$291M -$32.5M -$162M -125% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-02
Q1 2021 -$130M -$82.8M -$8.38M -11.3% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-03
Q4 2020 -$121M -$95.6M -$36.6M -62.1% Oct 1, 2020 Dec 31, 2020 10-K 2021-02-23
Q3 2020 -$84.8M -$80.6M -$14.8M -22.5% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-02
Q2 2020 -$70M $129M +$184M Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-03
Q1 2020 -$254M -$74.4M -$161M -186% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-04
Q4 2019 -$93.1M -$59M +$1.69M +2.78% Oct 1, 2019 Dec 31, 2019 10-K 2021-02-23
Q3 2019 -$94.8M -$65.8M -$15.2M -30.1% Jul 1, 2019 Sep 30, 2019 10-K 2021-02-23
Q2 2019 -$79.6M -$55.3M -$8.82M -19% Apr 1, 2019 Jun 30, 2019 10-K 2021-02-23
Q1 2019 -$70.8M $86.9M +$134M Jan 1, 2019 Mar 31, 2019 10-K 2021-02-23
Q4 2018 -$205M -$60.6M -$22M -56.7% Oct 1, 2018 Dec 31, 2018 10-K 2020-02-27
Q3 2018 -$183M -$50.6M -$4.83M -10.5% Jul 1, 2018 Sep 30, 2018 10-K 2020-02-27
Q2 2018 -$178M -$46.5M -$2.82M -6.46% Apr 1, 2018 Jun 30, 2018 10-K 2020-02-27
Q1 2018 -$175M -$46.9M -$6.01M -14.7% Jan 1, 2018 Mar 31, 2018 10-K 2020-02-27
Q4 2017 -$169M -$38.7M -$9.41M -32.1% Oct 1, 2017 Dec 31, 2017 10-K 2019-02-28
Q3 2017 -$160M -$45.7M -$28M -158% Jul 1, 2017 Sep 30, 2017 10-K 2019-02-28
Q2 2017 -$132M -$43.7M -$29.3M -205% Apr 1, 2017 Jun 30, 2017 10-K 2019-02-28
Q1 2017 -$102M -$40.9M -$26.1M -176% Jan 1, 2017 Mar 31, 2017 10-K 2019-02-28
Q4 2016 -$76.2M -$29.3M -$16.1M -121% Oct 1, 2016 Dec 31, 2016 10-K 2018-02-20
Q3 2016 -$60.1M -$17.7M -$4.79M -37.1% Jul 1, 2016 Sep 30, 2016 10-K 2018-02-20
Q2 2016 -$55.3M -$14.3M -$1.87M -15% Apr 1, 2016 Jun 30, 2016 10-K 2018-02-20
Q1 2016 -$53.4M -$14.8M -$3.4M -29.7% Jan 1, 2016 Mar 31, 2016 10-K 2018-02-20
Q4 2015 -$50M -$13.2M -$3.85M -41.1% Oct 1, 2015 Dec 31, 2015 10-K 2017-02-22
Q3 2015 -$46.2M -$12.9M -$3.22M -33.2% Jul 1, 2015 Sep 30, 2015 10-K 2017-02-22
Q2 2015 -$43M -$12.5M -$3.21M -34.7% Apr 1, 2015 Jun 30, 2015 10-K 2017-02-22
Q1 2015 -$39.8M -$11.4M -$3.54M -44.8% Jan 1, 2015 Mar 31, 2015 10-K 2017-02-22
Q4 2014 -$36.2M -$9.38M +$356K +3.66% Oct 1, 2014 Dec 31, 2014 10-K 2016-02-25
Q3 2014 -$36.6M -$9.7M -$4.29M -79.4% Jul 1, 2014 Sep 30, 2014 10-K 2016-02-25
Q2 2014 -$32.3M -$9.25M -$4.98M -117% Apr 1, 2014 Jun 30, 2014 10-K 2016-02-25
Q1 2014 -$27.3M -$7.89M -$4.55M -136% Jan 1, 2014 Mar 31, 2014 10-K 2016-02-25
Q4 2013 -$22.8M -$9.74M -$7.58M -351% Oct 1, 2013 Dec 31, 2013 10-K 2015-03-10
Q3 2013 -$15.2M -$5.41M -$2.42M -80.8% Jul 1, 2013 Sep 30, 2013 10-K 2015-03-10
Q2 2013 -$12.8M -$4.27M -$1.41M -49.2% Apr 1, 2013 Jun 30, 2013 10-K 2015-03-10
Q1 2013 -$11.4M -$3.34M -$1.15M -52.7% Jan 1, 2013 Mar 31, 2013 10-K 2015-03-10
Q4 2012 -$10.2M -$2.16M Oct 1, 2012 Dec 31, 2012 10-K 2014-03-13
Q3 2012 -$2.99M Jul 1, 2012 Sep 30, 2012 10-K 2014-03-13
Q2 2012 -$2.86M Apr 1, 2012 Jun 30, 2012 10-K 2014-03-13
Q1 2012 -$2.19M Jan 1, 2012 Mar 31, 2012 10-K 2014-03-13
* An asterisk sign (*) next to the value indicates that the value is likely invalid.